Design Therapeutics, Inc. Operating Income
Design Therapeutics, Inc. (DSGN) reported Operating Income of -$22.18 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-03
- Design Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$22.18M.
- Design Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$19.71M.
- Design Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$18.17M.
- Design Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$19.31M.
- Design Therapeutics, Inc. operating income (loss) for fiscal 2025 was -$79.47M.
- Design Therapeutics, Inc. operating income (loss) for fiscal 2024 was -$62.38M.
- Design Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$78.19M.
- Design Therapeutics, Inc. operating income (loss) for fiscal 2022 was -$67.59M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$22.18M 10-Q · filed 2026-08-03 | -$41.88M 10-Q · filed 2026-08-03 | -$60.05M derived: sum of 3 quarters · filed 2026-08-03 | -$79.36M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$19.71M 10-Q · filed 2026-04-28 | -$37.88M derived: sum of 2 quarters · filed 2026-04-28 | -$57.19M derived: sum of 3 quarters · filed 2026-04-28 | -$78.75M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$18.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$37.48M derived: sum of 2 quarters · filed 2026-03-09 | -$59.05M derived: sum of 3 quarters · filed 2026-08-03 | -$79.47M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$19.31M 10-Q · filed 2025-11-05 | -$40.88M derived: sum of 2 quarters · filed 2026-08-03 | -$61.30M 10-Q · filed 2025-11-05 | -$77.99M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$21.57M 10-Q · filed 2026-08-03 | -$41.99M 10-Q · filed 2026-08-03 | -$58.68M derived: sum of 3 quarters · filed 2026-08-03 | -$74.93M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$20.42M 10-Q · filed 2026-04-28 | -$37.11M derived: sum of 2 quarters · filed 2026-04-28 | -$53.36M derived: sum of 3 quarters · filed 2026-04-28 | -$68.40M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | -$16.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$32.94M derived: sum of 2 quarters · filed 2026-03-09 | -$47.98M derived: sum of 3 quarters · filed 2026-03-09 | -$62.38M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$16.25M 10-Q · filed 2025-11-05 | -$31.29M derived: sum of 2 quarters · filed 2025-11-05 | -$45.69M 10-Q · filed 2025-11-05 | -$60.81M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$15.04M 10-Q · filed 2025-08-07 | -$29.44M 10-Q · filed 2025-08-07 | -$44.56M derived: sum of 3 quarters · filed 2025-08-07 | -$63.39M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$14.40M 10-Q · filed 2025-05-07 | -$29.52M derived: sum of 2 quarters · filed 2025-05-07 | -$48.34M derived: sum of 3 quarters · filed 2025-05-07 | -$70.94M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$15.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$33.94M derived: sum of 2 quarters · filed 2025-03-10 | -$56.54M derived: sum of 3 quarters · filed 2025-03-10 | -$78.19M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$18.82M 10-Q · filed 2024-11-07 | -$41.42M derived: sum of 2 quarters · filed 2024-11-07 | -$63.07M 10-Q · filed 2024-11-07 | -$82.46M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$22.60M 10-Q · filed 2024-08-05 | -$44.25M 10-Q · filed 2024-08-05 | -$63.64M derived: sum of 3 quarters · filed 2024-08-05 | -$82.83M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | -$21.65M 10-Q · filed 2024-05-08 | -$41.04M derived: sum of 2 quarters · filed 2024-05-08 | -$60.23M derived: sum of 3 quarters · filed 2024-05-08 | -$75.87M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$19.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$38.58M derived: sum of 2 quarters · filed 2024-03-19 | -$54.22M derived: sum of 3 quarters · filed 2024-03-19 | -$67.59M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$19.19M 10-Q · filed 2023-11-13 | -$34.83M derived: sum of 2 quarters · filed 2023-11-13 | -$48.20M 10-Q · filed 2023-11-13 | -$59.33M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$15.64M 10-Q · filed 2023-08-14 | -$29.01M 10-Q · filed 2023-08-14 | -$40.14M derived: sum of 3 quarters · filed 2023-08-14 | -$51.47M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$13.37M 10-Q · filed 2023-05-09 | -$24.50M derived: sum of 2 quarters · filed 2023-05-09 | -$35.83M derived: sum of 3 quarters · filed 2023-05-09 | -$43.52M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$11.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$22.46M derived: sum of 2 quarters · filed 2023-03-14 | -$30.15M derived: sum of 3 quarters · filed 2023-03-14 | -$35.83M 10-K · filed 2023-03-14 |
| 2021-09-30 | -$11.34M 10-Q · filed 2022-11-03 | -$19.02M derived: sum of 2 quarters · filed 2022-11-03 | -$24.70M 10-Q · filed 2022-11-03 | -$28.57M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$7.69M 10-Q · filed 2022-08-08 | -$13.37M 10-Q · filed 2022-08-08 | -$17.23M derived: sum of 3 quarters · filed 2022-08-08 | -$19.61M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$5.68M 10-Q · filed 2022-05-09 | -$9.54M derived: sum of 2 quarters · filed 2022-05-09 | -$11.92M derived: sum of 3 quarters · filed 2022-05-09 | -$13.39M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$3.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$6.24M derived: sum of 2 quarters · filed 2022-03-10 | -$7.71M derived: sum of 3 quarters · filed 2022-03-10 | -$8.33M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$2.38M 10-Q · filed 2021-11-09 | -$3.85M derived: sum of 2 quarters · filed 2021-11-09 | -$4.47M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$1.46M 10-Q · filed 2021-08-09 | -$2.09M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$623.00K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |